Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neelkanth Limited reported audited financial results for Q4 and full year ended March 31, 2026. Total income for FY26 was Rs 65,026.83 Lakhs, up 8.5% from Rs 59,951.42 Lakhs in FY25. Net profit after tax for FY26 stood at Rs 6,613.47 Lakhs, nearly doubling from Rs 3,053.01 Lakhs in the previous year. Q4 FY26 net profit was Rs 2,170.49 Lakhs. The company operates in the Pharmaceuticals segment with two USFDA-approved manufacturing facilities in Andhra Pradesh and Maharashtra. The company cleared MFDS-Korea inspection at its Patalganga facility with zero observations in April 2026. New Labour Codes implementation resulted in an exceptional charge of Rs 360.39 Lakhs for increased gratuity and leave liability. The company opted for the new tax regime from FY 2026-27, leading to a deferred tax write-off of Rs 551.67 Lakhs.
Strong profit growth year-on-year with PAT more than doubling. Regulatory approvals and operational expansion in pharmaceuticals are positive signs for shareholders. However, one-time charges from labour reforms and tax regime change will impact near-term earnings.